- Home
- MCRI vs NRIX Comparison
MCRI vs NRIX Comparison
Compare MCRI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MCRI | NRIX |
|---|---|---|
| Founded | 1972 | 2009 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MCRI | NRIX |
|---|---|---|
| Price | $98.33 | $19.30 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $97.60 | $27.46 |
| AVG Volume (30 Days) | 86.1K | ★ 1.9M |
| Earning Date | 02-10-2026 | 01-27-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.41 | N/A |
| Revenue | ★ $539,635,000.00 | $83,687,000.00 |
| Revenue This Year | $6.34 | $59.40 |
| Revenue Next Year | $3.92 | N/A |
| P/E Ratio | $22.30 | ★ N/A |
| Revenue Growth | 4.61 | ★ 48.32 |
| 52 Week Low | $69.99 | $8.18 |
| 52 Week High | $113.88 | $22.50 |
Technical Indicators
Market Signals| Indicator | MCRI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 62.13 |
| Support Level | $96.55 | $18.79 |
| Resistance Level | $101.06 | $19.84 |
| Average True Range (ATR) | 1.55 | 1.13 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 48.52 | 37.06 |
Price Performance
Historical ComparisonAbout MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.